Speletas Matthaios, Voulgaridi Ioanna, Bogogiannidou Zacharoula, Sarrou Styliani, Kyritsi Maria A, Theodoridou Aikaterini, Dadouli Katerina, Matziri Alexia, Vontas Alexandros, Pappa Dimitra, Konstantinou Adamos-Konstantinos, Tsigalou Christina, Kalala Fani, Mouchtouri Varvara A, Hadjichristodoulou Christos
Department of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
Vaccines (Basel). 2023 Dec 21;12(1):12. doi: 10.3390/vaccines12010012.
During the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From December 2020 to February 2023, a cohort study was conducted to estimate IgG and IgA immunogenicity and the dynamics of booster mono- and bivalent COVID-19 mRNA vaccines in 260 individuals (male/female: 114/146, median age: 68 years, interquartile range (IQR) = 31) who initially received either mRNA (218) or adenovirus-vector-based vaccines (42). Participants were followed until the 90th day after the third booster dose. Our cohort study indicated a beneficial effect of booster vaccination on the magnitude of IgG and IgA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We found that second and third booster doses were more protective than one against fatal disease ( = 0.031, OR 0.08). In conclusion, booster COVID-19 vaccination should be strongly recommended, especially to individuals at high risk for severe/fatal disease.
在冠状病毒病（COVID-19）大流行后的时代，一个主要问题是加强疫苗接种对重症COVID-19是否有效以及是否应予以推荐，特别是对于重症疾病高危个体（即老年人或患有其他严重合并症的人）。从2020年12月至2023年2月，进行了一项队列研究，以评估260名个体（男/女：114/146，中位年龄：68岁，四分位间距（IQR）=31）中加强接种单价和二价COVID-19 mRNA疫苗后的IgG和IgA免疫原性及动态变化，这些个体最初接种的是mRNA疫苗（218人）或腺病毒载体疫苗（42人）。对参与者进行随访直至第三次加强剂量接种后的第90天。我们的队列研究表明加强疫苗接种对IgG和IgA严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体水平有有益影响。我们发现第二剂和第三剂加强针比一剂加强针在预防致命疾病方面更具保护作用（ = 0.031，OR 0.08）。总之，应强烈推荐加强接种COVID-19疫苗，特别是对于重症/致命疾病高危个体。
Zotero 插件
